Patent · US Active

Monoclonal antibody directed to FGFR1

US11597771B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Inventors

Christel Iffland · Cambridge, US
Christina Esdar · Darmstadt, DE
Xinyan Zhao · Longbeilingcun, CN
Qi An · Nashua, US
Johannes Tsung-Han Yeh · Billerica, US
Gang Hao · Belmont, US
Lars Toleikis · Kleinniedesheim, DE
Vanita D. Sood · Somerville, US
David Nannemann · Woburn, US
Robin Lytle · Acton, US
Bjoern Hock · Maintal, DE

Key dates

Filing date	Nov 21, 2017
Grant date	Mar 7, 2023
Priority date	—
Expiry date	Dec 8, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.